| patient | 0.63 |
| tumor | 0.56 |
| cancer | 0.56 |
| people | 0.56 |
| melanoma | 0.55 |
| child | 0.54 |
| combination | 0.51 |
| single family | 0.50 |
| primary tumor | 0.48 |
| cancer cells | 0.48 |
| More » |
| occur in exon | 0.62 |
| occur in codon | 0.59 |
| occur in gene | 0.58 |
| produce protein | 0.58 |
| change single protein b… | 0.58 |
| occur by chance | 0.57 |
| occur in fact | 0.55 |
| accumulate over time | 0.54 |
| drive carcinogenesis | 0.54 |
| enable mutant organism | 0.54 |
| More » |
| reduction | 0.65 |
| disease | 0.62 |
| cystic fibrosis | 0.59 |
| frameshift | 0.55 |
| a loss of information | 0.49 |
| loss of function | 0.48 |
| rp | 0.48 |
| condition | 0.46 |
| syndrome | 0.44 |
| mo | 0.44 |
| More » |
| little effect | 0.63 |
| effect | 0.62 |
| same effect | 0.59 |
| minor effect | 0.58 |
| significant effect | 0.55 |
| impact | 0.55 |
| profound effects | 0.51 |
| consequence | 0.50 |
| deleterious effects | 0.49 |
| negative effect | 0.46 |
| More » |
| random | 0.77 |
| neutral | 0.74 |
| rare | 0.73 |
| harmful | 0.69 |
| heterozygous | 0.68 |
| common | 0.66 |
| novel | 0.65 |
| somatic | 0.64 |
| deleterious | 0.64 |
| beneficial | 0.64 |
| More » |
| cancer | 0.63 |
| amino acid substitutions | 0.57 |
| amino acid changes | 0.55 |
| cancer development | 0.53 |
| evolution | 0.53 |
| a premature stop codon | 0.51 |
| increase | 0.51 |
| shift | 0.50 |
| premature stop | 0.50 |
| genomic instability | 0.49 |
| More » |
| change | 0.72 |
| permanent change | 0.61 |
| sudden change | 0.29 |
| single base changes | 0.25 |
| a base-pair sequence ch… | 0.25 |
| certainty | 0.25 |
| clinical applications o… | 0.25 |
| inherited | 0.66 |
| shown in table | 0.66 |
| associated with resista… | 0.66 |
| confirmed | 0.63 |
| selected | 0.63 |
| confirmed by dna sequen… | 0.62 |
| confirmed by sanger seq… | 0.61 |
| associated with disease | 0.61 |
| tested | 0.61 |
| favored by natural sele… | 0.59 |
| More » |
| occult infection | 0.25 |